Immunic Inc Stock Price, News & Analysis

Immunic (Nasdaq: IMUX) announced its financial results for Q2 2022 and provided updates on its clinical programs. The company reported a net loss of $21.9 million for the quarter, with cash reserves of $88.1 million expected to sustain operations through Q4 2023. Key upcoming clinical milestones include initial activity results for IMU-935 in psoriasis expected in Q4 2022 and unblinded safety data for IMU-856 anticipated in Q3 2022. Immunic remains optimistic about the potential of vidofludimus calcium in multiple sclerosis despite previous challenges in ulcerative colitis trials.

Immunic, Inc. (Nasdaq: IMUX), a biopharmaceutical company focused on chronic inflammatory and autoimmune diseases, announced CEO Daniel Vitt will speak at the 2022 Wedbush PacGrow Virtual Healthcare Conference on August 9, 2022, at 8:00 am ET. The conference runs from August 9-10. A live webcast will be accessible on the company's website, with an archived replay available for 90 days. Immunic is advancing therapies targeting conditions like multiple sclerosis and psoriasis.

Immunic, Inc. (Nasdaq: IMUX) will announce its financial results for Q2 2022, ending June 30, on August 4, 2022, prior to U.S. market opening. A webcast will follow at 8:00 am ET, with registration available through their website. The company develops selective oral immunology therapies aimed at chronic inflammatory and autoimmune diseases, with products like IMU-838 for multiple sclerosis and IMU-935 for psoriasis and prostate cancer.

Immunic, Inc. (Nasdaq: IMUX) announced the appointment of Maria Törnsén to its Board of Directors, effective July 5, 2022. Törnsén brings 20 years of global commercial experience in the biopharmaceutical sector. She replaces Jan Van den Bossche, who stepped down after six years. Chairman Duane Nash emphasized Törnsén's sales and marketing expertise will enhance the company's strategic focus as it advances its clinical programs, particularly the phase 3 ENSURE program targeting multiple sclerosis with its lead asset, vidofludimus calcium.

Immunic, Inc. (Nasdaq: IMUX) announced its participation in three key industry conferences this July focused on immunology therapies. From July 5-6, members will attend the 3rd FORUM Science & Health: Medicine of the Future in Fürstenfeldbruck, Germany. Notably, Evelyn Peelen, Ph.D., will present findings on IMU-935, an oral IL-17 inhibitor, at the 16th World Immune Regulation Meeting from July 6-9 in Davos, Switzerland. Additionally, Dr. Peelen will discuss IMU-935 at the B & T Cell-Mediated Autoimmune Disease Drug Development Summit from July 26-28 in Boston.

On June 15, 2022, Immunic, Inc. (Nasdaq: IMUX) announced the publication of positive results from its phase 2 EMPhASIS trial of vidofludimus calcium in patients with relapsing-remitting multiple sclerosis (RRMS). The study demonstrated that treatment significantly reduced MRI lesion counts by 62% and 70% for 45 mg and 30 mg doses, respectively, compared to placebo. The drug was found to be safe and well-tolerated, with no significant adverse effects. Following these findings, Immunic is progressing with its phase 2 CALLIPER trial and phase 3 ENSURE program, aiming to explore further potential of vidofludimus.

Immunic, Inc. (Nasdaq: IMUX), a biopharmaceutical company focused on oral immunology therapies for chronic inflammatory and autoimmune diseases, announced its participation in several conferences this June. Highlights include a presentation on IMU-935, a novel oral IL-17 inhibitor, at the 13th International Congress on Autoimmunity from June 10-13 in Athens, Greece. The company will also hold meetings during the BIO International Convention in San Diego from June 12-16 and participate in the JMP Securities Life Sciences Conference on June 15-16 in New York.

Immunic reported results from its phase 2 CALDOSE-1 trial of vidofludimus calcium (IMU-838) for ulcerative colitis, which failed to meet the primary endpoint of clinical remission. Unexpected interference with corticosteroids was noted, where patients on steroids showed lower remission rates. The company will not pursue further UC development independently and will focus on ongoing multiple sclerosis trials instead. As of May 31, 2022, Immunic reported $93.1 million in cash, projected to last until Q4 2023.

Immunic, Inc. (Nasdaq: IMUX) announced its Q1 2022 financial results, reporting a net loss of $20.8 million ($0.74 per share), down from a loss of $34.5 million in Q1 2021. Research and development expenses increased to $17.4 million, while general and administrative expenses rose to $4.0 million. The company expects its cash reserves of $95.7 million will fund operations into Q3 2023. Notable clinical milestones include upcoming top-line data from the Phase 2 CALDOSE-1 trial of vidofludimus calcium in ulcerative colitis, expected next month.